Actilyse (alteplase) is commonly used in situations involving acute or unstable symptom patterns to provide supportive therapeutic benefit by addressing symptoms related to acute vascular blockages. The medicine is used in areas where short-term symptomatic assistance is appropriate and is relevant in contexts involving heightened systemic burden.

It is used for managing conditions characterized by sudden and pronounced symptomatic episodes, primarily acute myocardial infarction (heart attack), acute massive pulmonary embolism (lung clot), and acute ischemic stroke (a clot-caused stroke). It may also be applied to help manage functional stability of occluded central venous access devices.

The purpose is to contribute to easing the overall symptom load that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Focus on Acute Symptom Management

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who can and cannot use Актилизе (Alteplase) — Official Regulatory Information

---

Eligibility scope

Populations for whom use is allowed (as stated in label): Generally adult patients (aged ge 18 years) for acute vascular conditions like acute ischemic stroke, provided no contraindications are present.

Populations for whom use is not recommended (if applicable): Systemic safety and efficacy for major indications are not established for the general pediatric population.

Populations for whom use is contraindicated: Absolute contraindications include evidence of active internal bleeding, history of intracranial hemorrhage, known intracranial lesions (aneurysm, tumor), or recent serious head trauma/surgery.

Age-related eligibility rules: The medicine is indicated for adults; no upper age limit is specified for some indications, though specific regulatory caution applies.

Condition-specific eligibility rules: Use is restricted for patients with severe uncontrolled hypertension, severe liver disease, or if taking anticoagulants resulting in an International Normalized Ratio ( INR) above the defined limit.

Pregnancy and lactation eligibility status (if explicitly documented): Use is restricted in pregnancy due to limited data, and caution is advised during lactation.

Eligibility-related restrictions: Use is restricted following recent major trauma or surgery and must adhere to specific time windows for acute ischemic stroke.

---

Eligibility classifications (high-level)

Eligibility severity classification (as defined in official documents): Non-eligibility is categorized as contraindicated (absolute prohibition) or not established (insufficient data).

Regulatory basis (EMA / FDA / etc.): Based on official regulatory documents.

Eligibility-context constraints (as defined in official documents): Eligibility is strictly limited by the high risk of major hemorrhage.

---

Resulting eligibility structure

Official eligibility statements: Use is contraindicated in patients with a history of CNS bleeding and active internal bleeding. Eligibility is strictly restricted by recent clinical events and conditions that affect coagulation.

Connection to the overall eligibility profile: Official regulatory labeling defines who can and cannot use Alteplase by prioritizing the avoidance of potentially fatal bleeding risks, especially those related to the central nervous system and underlying coagulation status. These rules establish clear limitations based on patient history, comorbidities, and age, ensuring use is confined to eligible adult populations.

Interactions with other medicines and products

Actilyse (alteplase) primarily interacts with other agents through pharmacodynamic effects, meaning the combination increases the risk of a shared adverse outcome, rather than affecting the concentration of alteplase itself.

Clinically Significant Interactions

The most significant interactions involve medicines that affect blood clotting or platelet function, substantially increasing the risk of bleeding or hemorrhage when used concurrently with alteplase.

Interacting Product Category	Effect Mechanism (Official Description)
Anticoagulants (e.g., heparin, warfarin)	Additive effect on hemostasis, increasing bleeding risk.
Antiplatelet Agents (e.g., aspirin, clopidogrel)	Additive inhibition of platelet function, increasing bleeding risk.

Another pharmacodynamic interaction involves Angiotensin-Converting Enzyme (ACE) Inhibitors. Concomitant use with alteplase may increase the risk of orolingual angioedema (swelling of the tongue or mouth), as noted in regulatory labeling.

Procedural and Timing Constraints

Administration guidelines include crucial restrictions to manage interaction risk. Actilyse must not be mixed with any other medicines, including heparin, in the same infusion vial or intravenous line due to physical and chemical incompatibility.

Furthermore, for patients treated for acute ischemic stroke, regulatory documents caution against the use of intravenous heparin and platelet aggregation inhibitors during the first 24 hours post-treatment due to insufficient investigation into safety in this specific timeframe and context.

How Актилизе Works

The mechanism of action for Актилизе (Alteplase) involves engagement with the endogenous fibrinolytic cascade.

Enzyme-Driven Lysis of the Fibrin Mesh

The drug functions as a recombinant tissue plasminogen activator (rt-PA), a specialized serine protease. Its action is concentrated on the blood clot via binding to fibrin, which forms the clot's structure. This binding enables the catalytic conversion of inactive plasminogen into its active form, the enzyme plasmin. This mechanism initiates the localized, enzymatic degradation of the clot structure.

Recanalization and Restoration of Flow Dynamics

The newly activated plasmin proceeds to chemically degrade the cross-linked fibrin polymers, physically dismantling the thrombus into smaller, soluble fragments. This structural dissolution removes the physical block. The resulting physiological effect is the recanalization (reopening) of the blood vessel, restoring flow dynamics to the compromised vascular territory.

Mechanistic Constraints

The drug's mechanism is constrained by the physical properties of the clot. Older thrombi feature a more complex, highly cross-linked fibrin structure, which limits the access of plasmin to its target sites. Furthermore, at high concentrations, the mechanism can activate circulating plasminogen, transiently leading to the depletion of circulating fibrinogen.

How to Use Актилизе (Alteplase) — Administration Guidelines

The administration of Актилизе, whose active ingredient is Alteplase, follows a strict standardized protocol. It is delivered solely through the parenteral route, which includes intravenous (IV) infusion for systemic treatment and instillation for local use, such as clearing an occluded central venous access device (CVAD).

The medicine is supplied as a lyophilized powder and requires careful preparation. It must be reconstituted only with the accompanying Sterile Water for Injection through gentle swirling; shaking is prohibited to avoid foaming. The final solution should not be combined with other medications in the same IV line.

Administration is a time-critical, single treatment instance for acute conditions, such as acute ischemic stroke (AIS), acute myocardial infarction (AMI), and pulmonary embolism (PE). Dosing is based on the patient's weight (mg/kg) but is subject to a maximum total dose, such as 90 mg for AIS. The total systemic dose is delivered in two mandatory sequential phases: an initial IV bolus (typically 10% of the total dose) followed immediately by the remainder administered as a continuous IV infusion over a prescribed duration, which may be 60 minutes, 90 minutes, or 2 hours, depending on the indication.

Weight-based dosing is a requirement for all systemic uses. For specific non-systemic use in children weighing less than 30 kg (CVCO), the dose is adjusted based on 110% of the catheter's internal volume, not to exceed 2 mg. This acute administration must occur exclusively in a monitored clinical environment.

Research evidence / Overview of studies for Актилизе

The information below summarizes the clinical research and evidence framework for Alteplase, focusing on the study structures, populations, and the patterns of findings documented by regulatory and scientific sources. This overview is non-advisory and focuses on what the research has explored, not on specific treatment recommendations.

---

Evidence for Use in Acute Ischemic Stroke

Research for this use was primarily conducted through large-scale, randomized controlled trials (RCTs). These studies involved adult patients presenting with symptoms of an acute ischemic stroke (a clot blocking blood flow to the brain). Researchers designed the trials to include patients based on the time elapsed since their symptoms began, often stratifying them into specific time windows. The main outcomes that studies monitored were the patient’s functional patterns and neurological status at 90 days, as well as all-cause mortality.

Studies report how patient functioning evolved in the observed populations during the 90-day follow-up period. Findings describe patterns related to the time of administration, with research observing a relationship between the measured outcomes and the timing of the administration. Long-term outcomes for patients beyond the standard 90-day follow-up are not extensively characterized in the primary pivotal research.

Evidence for Use in Acute Myocardial Infarction (Heart Attack)

The evidence framework for this application involved very large-scale, comparative RCTs including a high volume of patients. These studies explored acute treatment in adult patients experiencing a heart attack. Researchers were focused on outcomes related to systemic or functional imbalance, specifically all-cause mortality measured at 30 days. Research also monitored the anatomical findings related to the blocked heart artery, known as patency, or openness.

Specific measurements of mortality at 30 days were reported in the patient groups receiving the study treatment compared to the comparator. The contemporary evidence base is focused on comparisons against newer, evolving alternative methods for restoring blood flow to the heart, which can introduce some heterogeneity in the overall research landscape.

Areas of Research Uncertainty and Gaps

Certainty remains low in specific areas of application. For instance, the treatment is highly time-dependent, meaning research highlights the relationship between outcomes measured during the study period and the time elapsed since symptom onset. This time-dependency contributes to the limited generalizability of the findings. Furthermore, subgroup findings are uncertain, with research still exploring optimal strategies for patients presenting with very mild symptoms or for those with specific comorbidities.

Common questions about Актилизе (FAQ)

---

Q: How quickly does Актилизе start to work after it is administered?

While the exact time it takes to see therapeutic effect can vary, the official pharmacology information indicates that the drug's initial half-life is very short—less than five minutes. The half-life is a measure of how quickly the body begins to clear the medicine. The drug's mechanism of action involves converting an inactive substance into an enzyme that breaks down the clot; this process is designed to begin shortly after the substance enters the bloodstream.

---

Q: Why is there a strict time limit for giving Актилизе for a stroke?

The administration of this medicine is restricted to a very narrow, time-critical window (typically within 3 to 4.5 hours of symptom onset) for acute ischemic stroke. Official regulatory approval is based on clinical trial data that demonstrated a positive balance of benefits versus risks only when the drug was administered within this specific period.

---

Q: What are the most common signs of an allergic reaction to Актилизе?

Although allergic reactions are considered uncommon, they are possible. According to official product safety information, reported signs include hives, rash, itching, swelling of the face, lips, or tongue, and difficulty breathing or wheezing.

---

Q: Can Актилизе cause damage to blood vessels or tissues surrounding the site of administration?

The most frequent side effect related to the administration site is local bleeding. Official documents report injection site haemorrhage (bleeding) and bruising (haematoma) at the site where the IV line was placed. Official guidelines require careful monitoring during and after administration to watch for and address this risk.

---

Q: What exactly happens if the recommended time window for administering Актилизе is exceeded?

The official drug labeling specifies the time period during which the medicine is approved and proven effective for use in acute conditions. Treatment outside of this established timeframe is considered unapproved and is not supported by the clinical safety and efficacy data reviewed by regulatory authorities.

---

Q: Does Актилизе interact with common pain medications like ibuprofen or naproxen?

Yes. Official safety information indicates that the medicine interacts with certain drug classes. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen, as well as antiplatelet agents and anticoagulants, may increase the overall risk of serious bleeding if used concurrently.

---

Q: Are there any known long-term side effects that appear months or years after receiving Актилизе?

Official regulatory documents primarily focus on safety outcomes observed during the treatment period and the immediate follow-up (e.g., up to 90 days). The long-term safety profile of the drug, such as the potential for effects like carcinogenesis (cancer development), has generally not been evaluated in long-term animal studies.

---

Q: Are there different concentrations or versions of the Актилизе product?

Yes. The medicine is supplied as a lyophilized (freeze-dried) powder in different vial sizes, such as 10 mg, 20 mg, 50 mg, or 100 mg. This powder is then reconstituted with a solvent to form a solution of 1 mg of alteplase per mL for administration.

---

Q: Is Актилизе ever administered through a direct injection rather than a controlled IV infusion?

The administration protocol involves two steps. The first step is an initial intravenous bolus, which is a rapid, direct injection of a specific amount (typically 10% of the total dose) over one minute. This is immediately followed by the remainder of the dose given as a slower, controlled intravenous infusion.

---

Q: Does treatment with Актилизе affect the chances of having another stroke in the future?

Clinical trial data from studies supporting the drug’s use in acute ischemic stroke indicate that the risk of a new ischemic stroke at the three-month follow-up period was similar for patients who received the medicine compared to those who received a placebo.

---

Q: How long does Актилизе or its effects remain in a patient's body after the infusion is complete?

The drug has a short duration in the system. Official pharmacological data indicates that the initial half-life is less than five minutes, and the terminal half-life—the time it takes for the drug concentration to reduce by half—is approximately 72 minutes.

---

Q: Can patients who have pre-existing conditions like diabetes receive Актилизе treatment?

Official information indicates that pre-existing conditions are critical factors for eligibility evaluation. Regulatory documents list conditions like diabetes as important risk factors. In some clinical contexts, such as a patient with diabetes who has had a previous stroke, the condition may be listed as a contraindication or precaution due to increased risks.

---

Q: What is the typical risk of having another stroke or serious event immediately after Актилизе treatment?

The primary serious risk immediately following treatment is the potential for symptomatic intracranial hemorrhage (bleeding in the brain). Clinical trial data reports the risk of this serious event and the occurrence of a new ischemic stroke within the 90-day follow-up period.

---

Q: Is the brand name Актилизе used in all countries where the drug is available?

No. The official brand name for the active ingredient, alteplase, varies globally based on the market. For instance, while it is known as Actilyse in Europe and some other regions, it is sold as Activase in the United States.

---

Q: Is it true that patients who receive Актилизе must lie flat for a long time afterward?

Following treatment, safety precautions are taken to minimize the risk of bleeding. Official precautions advise limiting movement as much as possible, often requiring patients to remain in bed after administration. This measure is taken to minimize the risk of bleeding.

---

Q: Can a fever after receiving Актилизе be a sign of a complication?

Yes. Official regulatory labeling explicitly lists fever as a reported adverse reaction following treatment with alteplase. Continuous patient monitoring is required during and after administration.

---

Q: What kind of follow-up blood tests are necessary after treatment with Актилизе?

Follow-up blood tests are necessary to guide subsequent therapy. Official guidelines detail that tests like the aPTT (activated partial thromboplastin time) are often required to determine when the patient can begin or resume anticoagulant therapy, such as with heparin, which is often needed to prevent new clots.

Storage Conditions

Actilyse (alteplase) storage is governed by strict regulatory rules to protect the product's integrity. The unopened lyophilized powder must be stored in its original package to ensure protection from light. The temperature for the powder must not exceed 30 C, though some formulations may require refrigeration (2 C to 8 C). The medicine must always be kept out of the sight and reach of children.

Stability and Handling

Once reconstituted with Sterile Water for Injection, the solution is chemically stable for only 24 hours if refrigerated (2 C to 8 C) or 8 hours at room temperature (25 C to 30 C). Vials must not be shaken during preparation, and the solution must not be mixed with other drugs.

Disposal Instructions

Any unused medicine or waste material must be disposed of in accordance with local requirements. The product should not be used after its expiry date.